中国卫生标准管理
中國衛生標準管理
중국위생표준관리
China Health Standard Management
2015年
24期
180-181
,共2页
力达霉素%肝肿瘤起始细胞%表型%调控作用%机制
力達黴素%肝腫瘤起始細胞%錶型%調控作用%機製
력체매소%간종류기시세포%표형%조공작용%궤제
Lidamycin%Liver tumor initiating cels%Phenotype%Regulation%Mechanism
目的：探讨力达霉素对肝肿瘤起始细胞表型的调控作用及机制。方法运用裸鼠皮下移植瘤模型，对力达霉素治疗肝癌Huh7肿瘤起始细胞效果展开检测，回顾相关作用机制。结果力达霉素可使肿瘤体积缩小，将肿瘤的发生时间推迟。深入研究示，力达霉素在肿瘤起始细胞作用的可能分子机制为：力达霉素在体内或体外，均可使CSK3β/β-catenin通路活性下调。结论力达霉素可在体内、体外对Huch7肝肿瘤起始细胞抑制，并使CSK3β/β-catenin通路活性下调，对肿瘤起始细胞被力达霉素抑制的可能分子机制有所揭示，为临床实验提供参考依据。
目的：探討力達黴素對肝腫瘤起始細胞錶型的調控作用及機製。方法運用裸鼠皮下移植瘤模型，對力達黴素治療肝癌Huh7腫瘤起始細胞效果展開檢測，迴顧相關作用機製。結果力達黴素可使腫瘤體積縮小，將腫瘤的髮生時間推遲。深入研究示，力達黴素在腫瘤起始細胞作用的可能分子機製為：力達黴素在體內或體外，均可使CSK3β/β-catenin通路活性下調。結論力達黴素可在體內、體外對Huch7肝腫瘤起始細胞抑製，併使CSK3β/β-catenin通路活性下調，對腫瘤起始細胞被力達黴素抑製的可能分子機製有所揭示，為臨床實驗提供參攷依據。
목적：탐토력체매소대간종류기시세포표형적조공작용급궤제。방법운용라서피하이식류모형，대력체매소치료간암Huh7종류기시세포효과전개검측，회고상관작용궤제。결과력체매소가사종류체적축소，장종류적발생시간추지。심입연구시，력체매소재종류기시세포작용적가능분자궤제위：력체매소재체내혹체외，균가사CSK3β/β-catenin통로활성하조。결론력체매소가재체내、체외대Huch7간종류기시세포억제，병사CSK3β/β-catenin통로활성하조，대종류기시세포피력체매소억제적가능분자궤제유소게시，위림상실험제공삼고의거。
Objective To discuss lidamycin’s regulation and mechanisms of hepatoma initiating cels phenotype. MethodsUsing transplanted subcutaneously in nude tumor model to detect lidamycin’s treatment effect on Huh7 tumor-initiating cel,and reviewed the relevant mechanisms.Results Lidamycin can significantly reduce the volume of tumor and delay the occurrence of tumor .Further study showed that lidamycin's effect on possible molecular mechanism in cancer initating cels was that whether lidamycin was in vivo or in vitro,it can significantly make CSK3β / β-catenin pathway activity to reduce.Conclusion Lidamycin can inhibit Huh7 liver tumor initiating cels in vitro and vivo,lower GSK3β/β-catenin pathway’s slight status, reveal tumor-initiating cels inhibited by lidamycin possible molecular mechanisms,and provide a reference for clinical trials.
